Institution
Charles University in Prague
Education•Prague, Czechia•
About: Charles University in Prague is a education organization based out in Prague, Czechia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 32392 authors who have published 74435 publications receiving 1804208 citations.
Topics: Population, Large Hadron Collider, Czech, Magnetization, Transplantation
Papers published on a yearly basis
Papers
More filters
Memorial Sloan Kettering Cancer Center1, BC Cancer Agency2, University of Southampton3, University of Bologna4, Fudan University5, Peking University6, Charles University in Prague7, University of Ulsan8, University of Helsinki9, Kindai University10, Ondokuz Mayıs University11, Jagiellonian University12, Rabin Medical Center13, Tel Aviv University14, China Medical University (Taiwan)15, Hebron University16, Sorbonne17, Janssen Pharmaceutica18, National Institutes of Health19
TL;DR: The study did not meet its primary end point in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup, but in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety.
Abstract: PURPOSEIbrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, d...
320 citations
TL;DR: With this study, >100 ABCB11 mutations are now identified and close surveillance of BSEP-deficient patients retaining their native liver, particularly those carrying 2 null mutations, is essential.
320 citations
TL;DR: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment and may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.
Abstract: Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. Objective: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. Methods: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo. Results: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p Conclusions: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment. Once-monthly administration may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.
320 citations
TL;DR: In this article, a unified discussion of the Yarkovsky effect in both the original, "diurnal" variant and also for the "seasonal" variant has been provided for meteorite-sized, regolith-free asteroid fragments.
320 citations
Tel-Hai Academic College1, Tel Aviv University2, University of Cambridge3, University of Milano-Bicocca4, University of Padua5, University of Kiel6, Hannover Medical School7, Boston Children's Hospital8, University of Düsseldorf9, Great Ormond Street Hospital10, Charles University in Prague11, Trinity College, Dublin12, University of Zurich13
TL;DR: In this article, mutations in JAK2 might be a common molecular event in acute lymphoblastic leukaemia associated with Down's syndrome, and the functional consequences of identified mutations were studied in mouse haematopoietic progenitor cells.
320 citations
Authors
Showing all 32719 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Ronald C. Petersen | 178 | 1091 | 153067 |
| P. Chang | 170 | 2154 | 151783 |
| Vaclav Vrba | 141 | 1298 | 95671 |
| Milos Lokajicek | 139 | 1511 | 98888 |
| Christopher D. Manning | 138 | 499 | 147595 |
| Yves Sirois | 137 | 1334 | 95714 |
| Rupert Leitner | 136 | 1201 | 90597 |
| Gerald M. Reaven | 133 | 799 | 80351 |
| Roberto Sacchi | 132 | 1186 | 89012 |
| S. Errede | 132 | 1481 | 98663 |
| Mark Neubauer | 131 | 1252 | 89004 |
| Peter Kodys | 131 | 1262 | 85267 |
| Panos A Razis | 130 | 1287 | 90704 |
| Vit Vorobel | 130 | 919 | 79444 |
| Jehad Mousa | 130 | 1226 | 86564 |